Avacta Therapeutics (AIM: AVCT) has appointed healthcare executive Dr Patrick Vink to its board as non-executive deputy chairman and senior independent director.

Avacta Therapeutics (AIM: AVCT) has secured a significant regulatory milestone after reaching an agreement with the US Food and Drug Administration on the pivotal trial design for its lead cancer

Avacta Group PLC announced that all resolutions were passed at its Annual General Meeting, with overwhelming shareholder support for each proposal.

Avacta Therapeutics (AIM: AVCT) has reported strong progress across its oncology pipeline in the first half of 2026, highlighting advances in both its clinical programmes and balance sheet ahead of

Avacta Therapeutics plc (AIM: AVCT) has strengthened its balance sheet after completing an oversubscribed £9 million equity fundraising, with proceeds earmarked primarily for reducing outstanding convertible bond debt and supporting

Avacta Group PLC (AIM: AVCT) unveiled encouraging new clinical data for its lead oncology candidate AVA6000 (faridoxorubicin) at the ASCO 2026 annual meeting, highlighting both promising efficacy and a potentially

Avacta Therapeutics (AIM: AVCT) has announced a boardroom transition, with Richard Hughes to be appointed non-executive chairman following the company’s Annual General Meeting on 22 June 2026.

Avacta Group plc has reported significant progress across its pre|CISION oncology platform in its unaudited preliminary results for the year ended December 31, 2025, as the company advances multiple cancer

Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026

Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with